Skip to Content
Global News Select

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion

By Ben Glickman


Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, giving the pharmaceutical giant access to Alpine's potential treatment for chronic kidney disease.

The companies said on Wednesday that Vertex would pay $65 a share for Alpine. Net of expected cash acquired, the deal is valued at around $4.6 billion.

Alpine Immune's lead candidate is being evaluated as a potential treatment for IgA nephropathy, a chronic kidney condition that can lead to end-stage-renal disease, and affects about 130,000 people in the U.S. The molecule, called povetacicept, is expected to enter Phase 3 development in the second half of this year, the companies said.

The acquisition is expected to close in the second quarter of 2024.


Write to Ben Glickman at

(END) Dow Jones Newswires

April 10, 2024 16:30 ET (20:30 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Market Updates

Sponsor Center